Posters

Accelerated (10mW/cm2) vs conventional (3mW/cm2) corneal collagen cross-linking for the treatment of progressive keratoconus

Poster Details

First Author: U.de Sanctis ITALY

Co Author(s):    L. Bertaina   R. Penna   M. Catalano   F. Grignolo           

Abstract Details

Purpose:

To compare the outcome of accelerated corneal collagen crosslinking (CXL) and conventional CXL.

Setting:

Department of Surgical Sciences, Ophthalmology Institute, University of Turin, Italy.

Methods:

Consecutive patients with progressive keratoconus were included: 32 eyes of 28 patients had accelerated CXL (30 minutes riboflavin 0.1% (Ricrolin, Sooft, Italy) presoak; 9 minutes of 10 mW/cm2 ultraviolet-A (UVA) exposure), and 49 eyes of 47 patients had conventional CXL (30 minutes riboflavin 0.1% presoak; 30 minutes of 3 mW/cm2 UVA exposure). The postoperative changes in Snellen uncorrected and corrected distance visual acuity (UDVA and CDVA), Pentacam HR (Oculus; Germany) mean keratometry (Km), central corneal thickness (CCT) and endothelial cell density (ECD) with accelerated and conventional CXL were compared. The follow-up was 1 year.

Results:

The improvement of postoperrative visual acuity was not significantly different (p>0.05) between methods. After accelerated CXL, the UDVA improved from 0.33±0.19 to 0.45±0.37 (p=0.08), and the CDVA from 0.67±0.22 to 0.75±0.23 (p=0.01); after conventional CXL, the UDVA improved from 0.30±0.23 to 0.36±0.22 (p=0.08), and the CDVA from 0.64±0.25 to 0.75±0.20 (p=0.001). The reduction of postoperative Km was statistically significant after conventional CXL (from 47.18±2.69 to 46.66±2.74; p=0.001), but not after accelerated CXL (from 47.10±3.98 to 47.13±3.91; p=0.87). The reduction of postoperative CCT was statistically significant (p<0.001), and comparable between methods. The postoperative ECD did not show significant changes with both methods.

Conclusions:

The efficacy and safety of accelerated CXL with 10 mW/cm2 UVA light exposure appear comparable to those of conventional CXL. However, a longer follow-up is necessary to validate these findings.

Financial Disclosure:

NONE